BridgeBio Pharma AAQS

Mitä BridgeBio Pharma tekee? BridgeBio Pharma Inc. is a US biotech company founded in 2015. The company is based in Palo Alto, California and specializes in researching and developing medications for rare diseases. BridgeBio's business model is based on a pipeline of rare diseases that have little or no existing treatment options. The company identifies, finances, and operates individual independent subsidiary companies with the goal of developing precision medicines for rare and genetic diseases. An important element of BridgeBio's business strategy is strategic collaboration with academic institutions and other companies to share research and development expertise. BridgeBio has various subsidiary companies, each specializing in the development of medications for a specific genetic disease. These include Eidos Therapeutics, QED Therapeutics, PellePharm, Navire Pharma, Origin Biosciences, CoA Therapeutics, Calcilytix Therapeutics, Phoenix Tissue Repair, and MyoKardia. Eidos Therapeutics is constantly searching for therapies for transthyretin-mediated amyloidosis (ATTR), a rare cardiovascular disease caused by the buildup of amyloid proteins in various parts of the body. The first FDA-approved eprodisate therapy became available in Japan in 2005, making Eidos Therapeutics one of the most promising subsidiary companies of BridgeBio. QED Therapeutics specializes in developing therapies for Gorlin syndrome and medulloblastoma, a type of brain tumor. PellePharm aims to develop a topical therapy for Gorlin syndrome that can be used to control and treat tumors and non-tumorous skin changes. Navire Pharma explores specific kinases that influence cell growth and cell death signaling pathways to identify healing methods for cancer patients. Calcilytix Therapeutics focuses on discovering a treatment solution for chronic kidney diseases, with a main focus on stopping or reducing the loss of kidney function. Overall, BridgeBio is dedicated to the development of precision medicines designed to combat the underlying genetic causes of rare diseases. The company also advances the field of precision medicine and works closely with doctors and patients to improve the diagnosis of rare diseases and optimize patient care. In 2019, BridgeBio Pharma announced a strategic partnership with the Pharmaceutical Research and Manufacturers of America (PhRMA). The goal of this collaboration is to improve awareness of rare diseases and create better access to new medications. BridgeBio hopes that the partnership will accelerate the development of therapies for rare diseases. In conclusion, BridgeBio Pharma Inc. is an innovative biotech company specializing in the development of precision medicines for the treatment of rare genetic diseases. With a business model based on collaboration with subsidiary companies and strategic partners, BridgeBio Pharma Inc. aims to revolutionize the treatment and cure of patients with rare genetic diseases. BridgeBio Pharma on yksi Eurpooliin suosituimmista yhtiöistä.